We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $73.75, marking a +0.41% move from the previous day. This change lagged the S&P 500's 0.45% gain on the day. At the same time, the Dow added 0.49%, and the tech-heavy Nasdaq gained 0.67%.
Heading into today, shares of the kidney dialysis provider had gained 1.31% over the past month, lagging the Medical sector's gain of 5.52% and the S&P 500's gain of 2.44% in that time.
DVA will be looking to display strength as it nears its next earnings release. On that day, DVA is projected to report earnings of $1.66 per share, which would represent year-over-year growth of 84.44%. Meanwhile, our latest consensus estimate is calling for revenue of $2.92 billion, up 3.38% from the prior-year quarter.
DVA's full-year Zacks Consensus Estimates are calling for earnings of $5.31 per share and revenue of $11.41 billion. These results would represent year-over-year changes of +48.74% and +0.04%, respectively.
Investors should also note any recent changes to analyst estimates for DVA. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DVA currently has a Zacks Rank of #1 (Strong Buy).
Looking at its valuation, DVA is holding a Forward P/E ratio of 13.84. For comparison, its industry has an average Forward P/E of 31.28, which means DVA is trading at a discount to the group.
Also, we should mention that DVA has a PEG ratio of 0.6. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. DVA's industry had an average PEG ratio of 2.37 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 69, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $73.75, marking a +0.41% move from the previous day. This change lagged the S&P 500's 0.45% gain on the day. At the same time, the Dow added 0.49%, and the tech-heavy Nasdaq gained 0.67%.
Heading into today, shares of the kidney dialysis provider had gained 1.31% over the past month, lagging the Medical sector's gain of 5.52% and the S&P 500's gain of 2.44% in that time.
DVA will be looking to display strength as it nears its next earnings release. On that day, DVA is projected to report earnings of $1.66 per share, which would represent year-over-year growth of 84.44%. Meanwhile, our latest consensus estimate is calling for revenue of $2.92 billion, up 3.38% from the prior-year quarter.
DVA's full-year Zacks Consensus Estimates are calling for earnings of $5.31 per share and revenue of $11.41 billion. These results would represent year-over-year changes of +48.74% and +0.04%, respectively.
Investors should also note any recent changes to analyst estimates for DVA. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DVA currently has a Zacks Rank of #1 (Strong Buy).
Looking at its valuation, DVA is holding a Forward P/E ratio of 13.84. For comparison, its industry has an average Forward P/E of 31.28, which means DVA is trading at a discount to the group.
Also, we should mention that DVA has a PEG ratio of 0.6. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. DVA's industry had an average PEG ratio of 2.37 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 69, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.